Designs and manufactures single-use medical devices. Provides vascular access products, including catheters and navigation systems. Now — the numbers.
The biggest line carries real weight, but it doesn’t decide everything on its own.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
This company is not turning a profit, so the market is pricing its sales instead: 2.9× for every dollar of annual revenue.
Against companies in its own sector, it looks cheaper than 64% of them.
Analysts' average target sits 19% above today's price.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit indicators sit around the sector average.
Clearly below the class average.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
Clearly below the class average.
Clearly above the class average — a step short of the very top.
Growth: Sales growth trails the sector average.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
An investor who bought at the very peak is down 66% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
It met or beat analyst expectations in 7 of the last 8 quarters — consistency is a promise kept.
Over the last 12 months, company executives reported 42 buys and 10 sells. Management buying with its own money is usually read as a good sign.
It pays out $1.36 per share each year — regular cash for whoever holds the stock.
A loss of $905.6M against $2.0B in annual sales. And on top of that, sales fell from the year before.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
On our five-subject report card, TFX sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: TFX’s sales are going backwards, and it closed last year at a loss. The road back runs through both.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.